Ehser Sandra, Chuang Jing Jing, Kleist Christian, Sandra-Petrescu Flavius, Iancu Mircea, Wang Daohu, Opelz Gerhard, Terness Peter
Institute of Immunology, University of Heidelberg, Heidelberg, Germany.
Hum Immunol. 2008 Mar;69(3):165-73. doi: 10.1016/j.humimm.2008.01.018. Epub 2008 Feb 29.
The most important antigen-presenting cells are dendritic cells (DCs), which play a central role in the initiation of immunity and tolerance. Their immunoregulatory properties offer the potential of donor-specific control of graft rejection after organ transplantation. It has not been clarified which DC subpopulations mediate tolerance, and the use of natural DCs for therapeutic applications is therefore problematic. Suppressive DCs can be generated in vitro by treating the cells with biologic, pharmacologic, or genetic agents. Here we discuss approaches for generating inhibitory DCs and present DC-based animal models for control of allograft rejection. A prerequisite of suppressive DCs for therapeutic application in clinical transplantation is a reproducible method for their generation as well as the induction of irreversible suppressive function. Based on lessons learned from the use of DCs as tools in clinical vaccine trials in cancer, we discuss the unknown aspects and risks of DC therapy in transplantation.
最重要的抗原呈递细胞是树突状细胞（DCs），它们在免疫和耐受的启动中起核心作用。其免疫调节特性为器官移植后供体特异性控制移植排斥提供了潜力。尚未明确哪些DC亚群介导耐受，因此将天然DC用于治疗应用存在问题。通过用生物、药理或基因试剂处理细胞，可以在体外产生抑制性DC。在这里，我们讨论产生抑制性DC的方法，并介绍用于控制同种异体移植排斥的基于DC的动物模型。抑制性DC用于临床移植治疗应用的一个先决条件是一种可重复的产生方法以及诱导不可逆的抑制功能。基于在癌症临床疫苗试验中使用DC作为工具所吸取的经验教训，我们讨论了DC治疗在移植中的未知方面和风险。
